Skip to content
The U.S. Food and Drug Administration’s Accelerated Approval Pathway enables the timely development of treatments for severely ill patients who have few if any […]
BIO coffee chat focuses on reimbursement for Accelerated Approval Pathway drugs Read More »
Despite a pressing demand, schizophrenia has had limited treatment. “Roughly 1% of the entire world population has schizophrenia,” said Boobalan Pachaiyappan, Managing Director and
BIO CEO 2025: New solution for the challenge of schizophrenia Read More »
The idea of AI supercharging drug development is stirring a lot of excitement. However, a realistic understanding of what AI can and can’t do
BIO CEO 2025: AI is a tool – not magic Read More »
While a couple of frontrunners have taken the early lead in the race to capture the market for obesity drugs, major pharmaceutical firms still
BIO CEO 2025: Exciting new directions for obesity drug research Read More »
January brought important changes for the roughly 53 million seniors enrolled in Medicare prescription drug plans. Some of these changes are automatic, while others
Medicare Part D plans are changing for 2025 – here’s what patients need to know Read More »
HIV is not the death sentence that it was decades ago. Yet, there is still much work to be done in the HIV advocacy
How to break down barriers in HIV care Read More »
Although illnesses like ulcerative colitis and Crohn’s disease are life-changing, gastrointestinal diseases are largely invisible, with little social recognition or understanding. For underserved communities
How COGI fights for policies to support BIPOC IBD patients Read More »
Over 30 representatives from biodefense companies joined the Biotechnology Innovation Organization (BIO) on Capitol Hill in November to meet with bipartisan congressional leaders to
BIO hosts fly-in focused on biodefense, calls for PAHPA reauthorization Read More »
Rep. Buddy Carter (R-GA) held a press conference on Dec. 4 to call on congressional leadership to pass pharmacy benefit manager (PBM) reform before
Rep. Buddy Carter calls for vote on PBM reform before end of year Read More »
Over 75% of clinical trial participants in the U.S. are white. This historical statistic has held true even today, even though the American population
The importance of caregivers in clinical trial diversity Read More »
